Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Non-Muscle Invasive Bladder Neoplasms 1

Interventions

pembrolizumab 302Carboplatin 228Cisplatin 157Gemcitabine 155Paclitaxel 154Pemetrexed 122Bevacizumab 121Docetaxel 105Oxaliplatin 84durvalumab 82Nivolumab 81Fluorouracil 81Dexamethasone 79Cyclophosphamide 78atezolizumab 77130-nm albumin-bound paclitaxel 73Fulvestrant 71Capecitabine 69Injections 65Leucovorin 64Cetuximab 63Rituximab 56Lenalidomide 52fludarabine 51venetoclax 46Prednisone 45Irinotecan 44enzalutamide 41Letrozole 41tislelizumab 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × pirarubicin × 90 days × Clear all
NCT07424287 2026-06-02

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Not yet recruiting
236 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡